CRMI Says Lower Audit Fee for Reanda Does Not Compromise Audit Quality

• China Regenerative Medicine appointed Reanda as auditor effective November 6, 2026, following Linksfield's resignation over an audit fee disagreement.
• The FY2026 audit fee is HKD 1 million, excluding disbursements, versus Linksfield's proposed HKD 1.25 million.
• Its audit committee attributed Linksfield's higher fee to engagement team changes, not significant changes in the group's operations.
• The committee concluded Reanda's lower fee would not compromise audit quality, citing sufficient staffing and more transparent audit planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRMI - China Regenerative Medicine International Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261106-12404740), on November 06, 2026, and is solely responsible for the information contained therein.